中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
2026-05-08
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT UBT38006 INJECTION
Learn More
All News
Select Year
2026
2025
2024
The Marketing Application of TUL’s Semaglutide Injection Accepted by the National Medical Products Administration
2025-01-24
TUL’s UBT251 Injection Receives Clinical Trial Approval for New Indication
2025-01-22
TUL’s Mupirocin Ointment Receives Marketing Approval
2024-12-05
TUL’s Cefuroxime Sodium for Injection Passes Generic Drug Consistency Evaluation in Quality and Efficacy
2024-11-15
TUL’s Cefotaxime for Injection (1.0g) Passes Generic Drug Consistency Evaluation in Quality and Efficacy
2024-10-25
TUL’s Amoxicillin Granules (0.125 g) Pass Generic Drug Consistency Evaluation in Quality and Efficacy
2024-10-16
TUL’s Insulin Degludec Marketing Application Accepted by the National Medical Products Administration
2024-10-14
TUL’s Class I Innovative Drug TUL12101 Eye Drops Completes First Patient Enrollment in China Phase IIa Clinical Study
2024-10-14
UBT251 Injection Completes Phase Ia Clinical Study in China
2024-08-12
The United Laboratories (Inner Mongolia) Co., Ltd. Receives Marketing Approval for Bulk Medicine Tazobactam
2024-06-27
Beineng An® Passes Generic Drug Consistency Evaluation in Quality and Efficacy
2024-01-18
Prev
1
2
3
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
